The breast cancer drug tamoxifen disrupted the natural cyclic fluctuation of endocannabinoid (AEA) levels across the estrous cycle in rat hypothalamus and pituitary, reducing AEA levels in all brain areas.
Read this if you are taking tamoxifen and want to understand its effects beyond breast cancer, or if you research endocannabinoid-endocrine interactions.
Disrupted cyclingTamoxifen abolished the normal cyclic fluctuation of brain endocannabinoid levels
What the researchers found
Hypothalamic and pituitary AEA levels normally fluctuate across the estrous cycle, varying by brain area and cycle phase. Tamoxifen treatment disrupted this cyclic pattern and reduced AEA levels throughout the brain. In the pituitary, AEA fluctuations resulted from changes in both synthesis (NAPE-PLD) and degradation (FAAH) enzyme expression. In the hypothalamus, AEA level changes occurred without measurable changes in these enzymes, suggesting alternative regulatory mechanisms.
Why it matters
Many breast cancer patients take tamoxifen for years. Understanding how it affects the brain's endocannabinoid system could explain some of tamoxifen's neurological side effects and inform strategies to manage them.
The numbers in context
- AEA levels fluctuate by brain area and estrous cycle phase
- Tamoxifen reduced AEA levels in all brain areas
- Pituitary NAPE-PLD expression increased in metestrus
- No FAAH or NAPE-PLD changes detected in hypothalamus
- Tamoxifen disrupted cyclic AEA fluctuation pattern
How the study worked
Rat estrous cycle study with tamoxifen treatment. Measured AEA levels, FAAH expression, and NAPE-PLD expression in hypothalamus and pituitary across cycle phases.
Who was studied
Female rats across the estrous cycle, with and without tamoxifen treatment
What this study cannot tell us
Rat reproductive cycles differ from human menstrual cycles. Tamoxifen doses may not perfectly model human exposure. Only two brain regions examined. The clinical significance of altered brain AEA levels is unclear.
How to read the evidence
Preclinical animal study with detailed neurochemical measurements. Provides mechanistic insight but limited clinical applicability.
When this study was published
Published in 2023. Contributes to understanding tamoxifen's broader neurological effects.
The bigger picture
The interaction between the endocrine and endocannabinoid systems is increasingly recognized as important for brain function. This study adds to evidence that hormonal therapies have broader neurochemical effects than traditionally appreciated.
Questions still open
- Do tamoxifen-treated breast cancer patients experience changes in endocannabinoid-related symptoms?
- Could supplemental cannabinoids offset tamoxifen's effects on brain AEA levels?
- Do other selective estrogen receptor modulators similarly affect the endocannabinoid system?
Read the original research
Long-Term Tamoxifen Effects in the Cyclic Interaction of the Endocannabinoid and Endocrine System in the Rat Central Nervous System.
Biomedicines, 11(3)
Citation
Fonseca, Bruno M; Bhowmick, Niloy; Cunha, Sara; Maia, João; Correia-da-Silva, Georgina; Teixeira, Natércia; Sá, Susana I. (2023). Long-Term Tamoxifen Effects in the Cyclic Interaction of the Endocannabinoid and Endocrine System in the Rat Central Nervous System.. Biomedicines, 11(3). https://doi.org/10.3390/biomedicines11030720